Novel Drug Reduced Bulging in Active and Chronic Thyroid Eye Disease

(MedPage Today) — ORLANDO — Infusions of the investigational monoclonal antibody veligrotug improved symptoms among patients with active and chronic thyroid eye disease, the phase III THRIVE clinical program showed.
By week 15 in 113 patients…

Source link : https://www.medpagetoday.com/meetingcoverage/aace/115658

Author :

Publish date : 2025-05-19 19:34:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Novel Drug Reduced Bulging in Active and Chronic Thyroid Eye Disease

Senate Dems Urge HHS to Undo Rule Barring Some Public Comments

New Dads, Non-Birthing Partners Less Likely to Get Prenatal Counseling on Vaccines

Related Posts

Routine Antibiotics Appear to Hold No Benefit in Non-Severe COVID-19

GLP-1 Leads to Similar Cognitive Outcomes as Other Diabetes Drugs, Trial Data Show

Best Intensive Care Unit Sedative? Head-to-Head Trial Weighs In

New Dads, Non-Birthing Partners Less Likely to Get Prenatal Counseling on Vaccines

Senate Dems Urge HHS to Undo Rule Barring Some Public Comments

IG Live May 20: The Attack on Medicaid

Routine Antibiotics Appear to Hold No Benefit in Non-Severe COVID-19

GLP-1 Leads to Similar Cognitive Outcomes as Other Diabetes Drugs, Trial Data Show

Best Intensive Care Unit Sedative? Head-to-Head Trial Weighs In

New Dads, Non-Birthing Partners Less Likely to Get Prenatal Counseling on Vaccines

Novel Drug Reduced Bulging in Active and Chronic Thyroid Eye Disease

Senate Dems Urge HHS to Undo Rule Barring Some Public Comments

IG Live May 20: The Attack on Medicaid

Biden Has Reason for Optimism, Despite Advanced Prostate Cancer Diagnosis

Categories

Archives